This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Eli Lilly (LLY) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
The Zacks Analyst Blog Highlights J&J, Roche, Eli Lilly and AbbVie
by Zacks Equity Research
J&J, Roche, Eli Lilly and AbbVie are part of The Zacks top Analyst Blog.
Merck (MRK) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, and COVID-19 antiviral pill, molnupiravir when the company reports Q3 earnings.
Novavax (NVAX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
On Novavax's (NVAX) third-quarter earnings call, investors' focus is likely to be on the sales figures of its COVID-19 vaccine.
AbbVie (ABBV) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
AbbVie (ABBV) third-quarter performance will likely reflect the impact of strong demand for immunology and aesthetics franchises. Investors will also enquire about ABBV's plans to counter Humira LOE.
Biogen (BIIB) to Report Q3 Earnings: Here's What to Expect
by Zacks Equity Research
Biogen's (BIIB) sales in the third quarter are likely to have been hurt by lower sales of Tecfidera and Spinraza.
Pharma Stock Roundup: JNJ Q3 Earnings Beat, RHHBY Sales Weak, LLY, ABBV Ink M&A Deals
by Kinjel Shah
J&J (JNJ) beats earnings and sales estimates for the third quarter. Eli Lilly (LLY) and AbbVie (ABBV) announce small acquisitions.
4 Biotech Stocks Set to Outpace Q3 Earnings Estimates
by Sundeep Ganoria
Let us take a look at some biotech stocks, ARGX, BMRN, LLY and GMAB, which are poised to beat on third-quarter earnings.
Eli Lilly (LLY) to Buy Hearing Loss Gene Therapy Maker Akouos
by Zacks Equity Research
Lilly (LLY) is set to acquire all the outstanding shares of Akouos for approximately $487 million plus a contingent value right for an aggregate amount up to approximately $610 million.
Akouos (AKUS) Surges on $610M Buyout Deal With Eli Lilly
by Zacks Equity Research
Akouos (AKUS) is set to be acquired by Eli Lilly for an aggregate amount of $610 million. The deal is expected to close in the fourth quarter of 2022. Stock up.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Eli Lilly (LLY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed at $332.76 in the latest trading session, marking a +0.41% move from the prior day.
The Zacks Analyst Blog Highlights Microsoft, Alphabet, Eli Lilly, Visa and Morgan Stanley
by Zacks Equity Research
Microsoft, Alphabet, Eli Lilly, Visa and Morgan Stanley are included in this Analyst Blog.
Top Analyst Reports for Microsoft, Alphabet & Eli Lilly
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Alphabet Inc. (GOOGL) and Eli Lilly and Company (LLY).
J&J (JNJ) to Start Q3 Earnings Season for Pharma Sector
by Zacks Equity Research
J&J's (JNJ) Pharma segment is expected to have performed above the market. In the MedTech segment, sales in the second half are expected to have been better than the first.
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Rigel (RIGL) to Not Pursue the WAIHA Program, Cut Jobs
by Zacks Equity Research
Rigel (RIGL) decides to back out from the label expansion of fostamatinib for the treatment of patients with warm autoimmune hemolytic anemia (wAIHA) following the FDA???s review.
Eli Lilly (LLY) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed at $323.89 in the latest trading session, marking a -0.85% move from the prior day.
Annovis (ANVS) Gains on FDA Authorization for AD Study
by Zacks Equity Research
Annovis (ANVS) shares jump following the FDA's authorization to proceed with the phase II/III clinical study of lead candidate buntanetap in moderate Alzheimer's Disease (AD).
Lilly's (LLY) Diabetes Drug Gets FDA Fast Track Tag for Obesity
by Zacks Equity Research
Eli Lilly (LLY) receives a fast-track designation from the FDA for tirzepatide to treat obesity in adult patients. The company will begin rolling NDA submission later this year.
Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed the most recent trading day at $321.55, moving -0.56% from the previous trading session.
Will Acquisitions Help Novo Nordisk (NVO) Combat Stiff Rivalry?
by Zacks Equity Research
Novo Nordisk (NVO) expects new acquisitions to diversify its portfolio of marketed drugs and help combat the stiff competition in the diabetes market.
Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PJP
LLY & PRTA in Spotlight on BIIB-Eisai's AD Drug Data
by Ekta Bagri
The success of Biogen (BIIB)-Eisai's AD candidate in a big phase III study makes investors optimistic about the prospects of other AD candidates as well.